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Abstract: Travoprost is a prostaglandin analogue widely used for reducing intraocular pressure 
(IOP) in patients affected with glaucoma and ocular hypertension. It exerts its ocular hypotensive 
effect through the prostaglandin FP receptors, located in the ciliary muscle and the trabecular 
meshwork. Several studies have shown that topical administration of travoprost induces a mean 
IOP reduction ranging from 25% to 32%, and sustained throughout the 24-hour cycle. When com-
pared with timolol, travoprost is more effective at reducing IOP, while generally no difference 
has been found in the head-to-head comparison with other prostaglandin analogues. The fixed 
combination of travoprost and timolol has demonstrated a hypotensive efficacy comparable to 
the concomitant administration of the two drugs. Recently, a new preservative-free formulation 
of travoprost 0.004% has been marketed for reducing tolerability-related problems in subjects 
affected with ocular surface disease. Low rates of topical and systemic adverse reactions, strong 
ocular hypotensive efficacy, and once-a-day dosing make travoprost a first-line treatment for 
patients affected with elevated IOP.
Keywords: prostaglandin analogue, glaucoma, ocular hypertension
Introduction
Glaucoma is the second leading cause of blindness in the world according to the World 
Health Organization. It is estimated that over 2.2 million Americans are affected by 
glaucoma, but only half of them are aware of the disease and properly treated.1 Studies 
estimate that the number of patients blind from glaucoma is between 5.2 and 6.7 million 
all around the world, with higher rates of blindness in developing countries, due to 
lack of detection and limited treatment options.2,3
Elevated intraocular pressure (IOP) is a major risk factor for glaucoma. Although 
glaucoma pathogenesis has not been completely understood, high IOP levels may directly 
damage axons of ganglion cells and reduce blood support to the optic nerve, resulting in 
ischemia and neurodegeneration.4 Additional factors are probably implicated, such as 
abnormalities of the ocular blood flow,5–7 loss of vascular autoregulation,8,9 and genetic 
predisposition.10 However, further research along these directions is needed. 
Reduction of IOP is the only proven treatment for glaucoma. The Early Manifest 
Glaucoma Trial demonstrated that in patients with early disease, the risk of progression 
decreased by 10% with each mmHg IOP reduction from baseline.11 These results were 
recently confirmed by the UK Glaucoma Treatment Study.12 Several surgical, laser, 
and pharmacological options are available for reducing IOP.13 However, pharmaco-
logical approach remains the mainstay of glaucoma therapy and a valuable option for 
most glaucoma patients. 
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Prostaglandin analogues (PGs) are a relatively new class 
of anti-glaucoma drugs that exert their ocular hypotensive 
effect through the prostaglandin FP receptors, located in 
the ciliary muscle and in the trabecular meshwork.14,15 
A low rate of topical and systemic adverse reactions, strong 
hypotensive efficacy, and once-a-day administration contrib-
uted to the widespread use of these drugs as first-line therapy 
in glaucoma. Travoprost, a synthetic PG, was introduced in 
the market in 2001, after approval by the US Food and Drug 
Administration (FDA) on March of the same year.
Pharmacology and pharmacokinetics
Travoprost is a synthetic derivative of naturally occurring 
PG F2α (PGF2α). Natural PGs, especially of the F series, 
are relatively polar and hydrophilic, and poorly penetrate cell 
membranes.16 Synthetic esterification in carbon-1 position 
gives travoprost lipophilic properties, increasing penetra-
tion though lipid membranes such as corneal epithelium.17,18 
During the corneal passage, travoprost isopropyl ester situ-
ated in carbon-1 position is hydrolyzed, generating an active 
free acid (Figure 1).14,15,19 
Travoprost free acid is a potent agonist of FP receptors, 
about ten-times more potent than latanoprost.14,19 In animal 
models, it reaches high concentration in anterior tissues of the 
eye (ie, anterior chamber and ciliary body), while very low con-
centrations are measurable in vitreous, retina, and choroid.20 
A drop of travoprost 0.004% contains 1.2 µg of travoprost 
prodrug. After bilateral administration, travoprost free acid 
reaches a maximum plasma level of 10-10 M, which remains 
constant after 7 days of administration (no accumulation).21 
Plasma half-life of travoprost acid is approximately 
45 minutes and less than 2% of topical ocular dose is excreted 
in the urine within 4 hours from administration.
Mechanism of action
Similar to other PGs, travoprost exerts its ocular hypotensive 
action mainly by increasing uveoscleral outflow, but some 
effects on trabecular meshwork may be present as well.22 
An increase in uveoscleral outflow was demonstrated both 
in monkeys23 and in patients affected by ocular hypertension 
(OHT) and treated with travoprost.24 No effect on aqueous 
humor production was described. 
Immunochemistry studies showed the presence of FP 
receptors in ciliary body and sclera.25 Several mechanisms 
have been proposed to explain the increase in uveoscleral 
outflow induced by PGs, such as remodeling of the extracel-
lular matrix;26,27 relaxation and modifications of the ciliary 
muscle shape;28,29 reorganization of actin and vinculin within 
muscle cells.30
Remodeling of the extracellular matrix within the ciliary 
body is probably the most studied mechanism of action 
of PGs. Travoprost stimulates secretion and activation of 
matrix metalloproteinase (MMP)2 in ciliary muscle cells 
through protein-kinase C and extracellular signals, regu-
lated by protein-kinase 1- and protein-kinase 2-dependent 
pathways.31,32 MMP2, together with MMP1 and MMP3, 
induces dissolution of type I and type III collagen of the 
extracellular matrix.33 Studies on monkeys treated with dif-
ferent types of PGs for 1 year showed an increase in optically 
empty spaces between ciliary body muscle bundles, partially 
filled with myelinated nerve fibers.34,35 Ultrastructurally, these 
spaces appeared covered with endothelial cells, at direct con-
tact with microvascular basement membranes. The described 
structures resemble a lymphatic drainage system, similar to 
the one described in the choroid.36 This reorganization of 
ciliary body may facilitate aqueous humor drainage from 
the anterior chamber and cause IOP reduction.
In vitro studies on cultured cells provide strong evidences 
about an effect of travoprost and other PGs on trabecular 
meshwork. Similarly to ciliary body, secretion and activa-
tion of MMPs initiate degradation of extracellular matrix, 
regulating outflow facility. MMPs are normally expressed 
by trabecular meshwork37 and control outflow resistance 
in human organ-cultured anterior segments.38 Experiments 
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Figure 1 Travoprost chemical structure. 
Notes: (A) Travoprost prodrug. (B) Travoprost free acid, after hydrolysis of isopropyl ester in carbon-1 position.
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on pig cultured trabecular meshworks, perfused at constant 
pressure, showed an increase in outflow facility up to 30% 
after intra-cameral injection of PGF2α.39 Histological studies 
on trabecular meshworks exposed to PGs demonstrated focal 
regions of endothelial cell loss and endothelial detachment 
into Schlemm’s canal, together with loss of extracellular 
matrix and consequent reduction of outflow resistance.40 
Interestingly, a study by Zhao et al showed that prolonged 
treatment of human trabecular meshwork cells with PGF2α 
increases expression of insulin-like growth-factor-1 (IGF-1) 
and fibroleukin.41 IGF-1 is known to stimulate expression 
of MMPs and the proteinase action of fibroleukin may be 
active against extracellular matrix, once again remodeling 
the microstructure of trabecular meshwork and reducing 
resistance to flow.
Efficacy
Many studies showed that topical administration of travo-
prost 0.004% reduces IOP in patients affected by primary 
open-angle glaucoma (POAG) and OHT.16,42 In an analytic 
review about the efficacy of PGs in patients affected by 
POAG, travoprost was found to induce a mean weighted 
IOP reduction of 28.7%.43 Similarly, a meta-analysis by 
van der Valk et al evaluating randomized clinical trials on 
most frequently prescribed glaucoma drugs estimated that 
travoprost is capable of an IOP reduction of between 31% 
(peak; 32%–29%) and 29% (trough; 32%–25%).44
Efficacy: 24-hour studies
In a short 6-week crossover study, Konstas et al evaluated 
24-hour efficacy of travoprost 0.004% dosed once in the eve-
ning versus in the morning.45 While there was no difference 
in mean 24-hour IOP between morning and evening admin-
istration (P=0.7), travoprost dosed in the evening achieved a 
significantly lower 24-hour IOP fluctuation (3.2±1.0 mmHg 
and 4.0±1.5 mmHg, respectively, for evening and morning 
dosing, P=0.001) and statistically lower IOP at the 10 am 
time-point (P=0.02). In this study, travoprost was effective 
in reducing IOP at all daytime and nighttime time-points, 
sustaining its hypotensive efficacy up to 24 hours after 
administration. Similarly, in a study comparing 24-hour 
IOP control with timolol/travoprost fixed combination (FC) 
versus travoprost alone,46 Konstas et al found that travoprost, 
dosed once in the evening, was effective at reducing IOP 
during the 24-hour cycle, with a mean 24-hour IOP reduc-
tion of 26.3%. 
A meta-analysis by Stewart et al investigating the 
short-term 24-hour efficacy of topical agents in glaucoma47 
reported that travoprost reduced mean 24-hour IOP by 27% 
from untreated baseline, with a similar hypotensive effect 
at diurnal and nocturnal time-points (P=0.064). Similar 
results were obtained in a small pilot study on patients 
affected by POAG and OHT by Dubiner et al. They evalu-
ated the persistency of travoprost IOP-lowering efficacy 
up to 84 hours after the last administration.48 Patients were 
treated in a masked fashion with travoprost 0.004% in the 
evening for 2 weeks and then IOP was measured every 
4 hours for 36 hours, and 60 and 84 hours after the last 
dose, with no additional medication. Travoprost induced 
significant IOP reductions from baseline at all time-points 
analyzed, up to 84 hours after the last dose (P0.001). 
The greatest decrease in IOP was registered at the 8 am time-
point (approximately 12 hours after dosing). 
Not many studies investigated 24-hour long-term 
persistency of travoprost hypotensive efficacy. In a recent 
study by Riva et al, travoprost 0.004% given as monotherapy 
in a cohort of 36 previously untreated POAG patients, induced 
a quite uniform 24-hour IOP reduction during the 5-year 
follow-up of the study (range of 24-hour IOP reduction: 
27.8%–28.6%, Figure 2).49 Interestingly, although mean 
nocturnal IOP reduction with travoprost was somewhat lower 
than mean daytime IOP reduction, there was no significant dif-
ference between nighttime and daytime efficacy (P0.05).
Comparison with timolol
Several studies comparing travoprost versus timolol have 
generally demonstrated a superior IOP control with the 
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Figure 2 Mean 24-hour, diurnal, and nocturnal intraocular pressure in a cohort of 
primary open-angle glaucoma patients treated with travoprost monotherapy and 
followed-up for 5 years. 
Note: Reprinted with permission from Riva i, Katsanos A, Floriani i, et al. Long-
term 24-hour intraocular pressure control with travoprost monotherapy in patients 
with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540.49
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former.50–54 Timolol was considered for a long time as a 
first-line therapy in glaucoma management, although during 
the last 2 decades a widespread use of PGs undermined this 
paradigm. Compared to PGs, initial lower costs of timolol 
medication are neutralized in the long-term by higher IOPs, 
more medication changes, greater incidence of glaucoma 
progression, and less persistency in original therapy.55
Goldberg et al randomized 573 patients affected by 
POAG and OHT to treatment with timolol 0.5% twice daily 
or travoprost (0.004% and 0.0015%) dosed once in the 
evening.50 Subjects enrolled had a mean IOP of approxi-
mately 26 mmHg. The primary efficacy variable was IOP 
measured at 9 am, 11 am, and 4 pm at baseline and during the 
9-month follow-up study visits. Mean diurnal IOP reduction 
was greater with travoprost 0.004% (range of IOP reduction: 
8–8.9 mmHg) than with timolol (range of IOP reduction: 
6.3–7.9 mmHg) (P0.001). Interestingly, travoprost 0.004% 
reduced IOP significantly more than travoprost 0.0015% 
only at the 11 am time-point (P=0.03), the time of peak 
drug activity.
In a similar 6-month study (ie, same protocol as the 
previous study) comparing travoprost to timolol, travoprost 
was superior to timolol in nine of 13 visits with differences 
in IOP reduction ranging from 0.9 to 1.8 mmHg (0.0015%), 
and in ten of 13 visits with differences in IOP reductions 
from 0.9 to 2.4 mmHg (0.004%).51 The IOP lowering effect 
of travoprost 0.0015% and travoprost 0.004% was similar.
In a study by Netland et al travoprost (0.004% and 
0.0015%) resulted in more effective reduction of diurnal 
IOP (mean of IOPs at 9 am, 11 am, and 4 pm) than timolol 
0.5% in 801 patients affected by POAG and OHT, with a 
baseline IOP of approximately 25 mmHg.52 Mean IOP over 
visits and time ranged from 17.9 to 19.1 mmHg (travoprost 
0.0015%), 17.7 to 19.1 mmHg (travoprost 0.004%), and 19.4 
to 20.3 mmHg (timolol 0.5%). Mean IOP in the travoprost 
0.004% group was lower than in the 0.0015% group at 13 of 
18 treatment visits, although this difference was not statisti-
cally significant.
A meta-analysis by Li et al compared travoprost 0.004% 
hypotensive efficacy with timolol 0.5% in patients affected 
by POAG or OHT.54 Four studies were included in this meta-
analysis for a total of 1,354 patients. Travoprost 0.004% 
resulted in being more effective than timolol 0.5% in lower-
ing IOP (weighted mean difference =0.81 mmHg in favor of 
travoprost, P0.001).
Comparison with other PGs
The majority of the studies comparing the efficacy of travo-
prost against other PGs have shown no significant differences 
in IOP-lowering ability.52,56–58 Similar mechanism of action 
and comparable effects on uveoscleral outflow and trabecular 
meshwork are probably at the basis of these results.
Parrish et al compared latanoprost, travoprost, and bimato-
prost in a head-to-head randomized 12-week prospective trial, 
including 410 patients affected by POAG and OHT.56 Mean 
IOP at baseline was similar among the three groups (latano-
prost: 25.7 mmHg, bimatoprost: 25.7 mmHg, and travoprost: 
25.5 mmHg). Adjusted IOP reductions in mean IOP at 8 am 
were similar (P=0.12), as were those at 12 pm, 4 pm, and 
8 pm. The estimated 8 am IOP reduction at 12 weeks was 
8.6±0.3 mmHg for latanoprost, 8.7±0.3 mmHg for bimato-
prost, and 8.0±0.3 mmHg for travoprost (Figure 3).
In a 12-month comparison of travoprost with latanoprost, 
Netland et al found no difference in IOP reduction between 
the two drugs at the 8 am and 10 am time-points, while 
travoprost 0.004% was slightly more effective at the 4 pm 
time-point (0.8 mmHg lower with travoprost than latanoprost, 
pooled data across visits).52 Interestingly, travoprost 0.004% 
reduced IOP in black patients by up to 2.4 mmHg more than 
latanoprost.
In 40 patients affected by pseudoexfoliative glaucoma 
and with a baseline 24-hour IOP of 25.1±2.5 mmHg, Konstas 
et al found no difference in IOP reduction between latano-
prost and travoprost at all diurnal and nocturnal time-points, 
apart from at the 6 pm assessment, where travoprost provided 
lower IOP than latanoprost (16.7±2.6 versus 17.9±2.5 mmHg, 
respectively, for travoprost and latanoprost).59 On the basis 
of these results, the authors speculated a possible greater 
hypotensive efficacy of travoprost in the late afternoon; 
however more studies are needed to confirm these data.
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Figure 3 Mean intraocular pressure with latanoprost, travoprost, and bimatoprost 
at baseline and after 12 weeks of treatment in a cohort of primary open-angle 
glaucoma and ocular hypertension patients.
Note: Reprinted from Am J Ophthalmol. 135(5):688–703. Parrish RK, Palmberg P, Sheu 
wP, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost 
in patients with elevated intraocular pressure: a 12-week, randomized, masked-
evaluator mul ticenter study. Copyright 2003 with permission from elsevier.56
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
37
.1
17
.1
2.
83
 o
n 
05
-N
ov
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
637
Travoprost 0.004% for glaucoma treatment
Cantor et al randomized 157 patients affected by POAG 
or OHT to treatment with travoprost 0.004% or bimatoprost 
0.003%, in a double-blind, parallel-group clinical trial.60 
At the 6-month visit, bimatoprost achieved greater IOP 
reduction than travoprost at the 9 am time-point (7.1 mmHg 
[27.9%] versus 5.7 mmHg [23.3%], respectively, for bimato-
prost and travoprost), while no significant differences were 
found between the two drugs at the 1 pm and 4 pm assess-
ment. In this study, patients were more likely to achieve 
clinically relevant IOP reductions 20%, 25%, or 30% with 
bimatoprost than travoprost at the 9 am time-point. 
A meta-analysis of published data by Li et al did not 
confirm these results and failed to find significant differences 
in hypotensive efficacy between travoprost and bimato-
prost (weighted mean difference: -0.08 mmHg in favor 
of bimatoprost, P=0.8).54 However, because baseline IOP 
values of patients included in the meta-analysis were from 
24 to 36 mmHg, the results can only be safely assumed in 
this IOP range.
Travoprost fixed and unfixed 
combination with timolol
Approximately 40% of patients affected by OHT require two 
or more topical medications to control IOP.61 When target 
IOP is not achieved with a single agent, combined therapy 
using drugs with different mechanism of action is recom-
mended. An FC of travoprost and timolol allows for reduction 
of adverse events and increases patients’ compliance. 
A few studies compared directly the hypotensive efficacy 
of timolol/travoprost FC against travoprost alone. Barnebey et 
al randomized 263 patients to travoprost 0.004% or timolol/
travoprost FC in a 3-month parallel-arm trial.53 The primary 
efficacy variable was mean IOP at 8 am, 10 am, and 4 pm com-
pared with baseline values. Timolol/travoprost FC decreased 
IOP by 0.9–2.4 mmHg more than travoprost, with a significant 
differences at seven of the nine study visits (P0.05). 
Konstas et al obtained similar results in a 24-hour cross-
over study.46 Thirty-two POAG and OHT patients were 
randomized to either timolol/travoprost FC or travoprost 
alone for 8 weeks and were then switched to the opposite 
treatment for another 8 weeks. Assuming a mean baseline 
24-hour IOP of 27.7 mmHg (range: 26.7–28.8 mmHg), 
timolol/travoprost FC induced a lower absolute IOP level 
for the 24-hour curve (17.2 mmHg versus 19.6 mmHg, 
respectively, for timolol/travoprost FC and travoprost) and 
at all time-points (P0.047).
Timolol/travoprost FC was compared to concomitant 
administration of timolol and travoprost in two studies with 
similar design.62,63 This point is of particular interest, as a 
recent meta-analysis by Quaranta et al64 evaluating overall 
hypotensive efficacy of β-blocker/PG FCs showed that 
concomitant administration is more effective than FC in 
patients affected by POAG and OHT. These two studies ran-
domized a total of 719 patients to a 3-month treatment with 
timolol/travoprost FC (administered once in the morning) 
or concomitant administration of timolol in the morning 
and travoprost in the evening (once daily both). Patients 
enrolled had IOP between 22 and 36 mmHg and IOP was 
assessed at three diurnal time-points (8 am, 10 am, and 
4 pm). Assuming a clinically significant difference between 
treatments of 1.5 mmHg (95.1% confidence limit), both the 
studies concluded that timolol/travoprost FC was compa-
rable in efficacy to concomitant administration of timolol 
and travoprost. Differences in mean diurnal IOP between 
treatment groups were 1.5 mmHg at seven of nine visits 
and at six of nine visits, respectively, in the first62 and the 
second study.63 However, a trend toward lower IOP values 
in the concomitant timolol and travoprost group was evident 
in both studies. Assuming that timolol in the concomitant 
medication group was dosed once-a-day and not twice daily, 
differences in efficacy between the two treatments may reach 
significance in clinical practice. Further studies are needed 
to confirm this hypothesis. 
Travoprost benzalkonium chloride-
free and travoprost 0.003%
Most anti-glaucoma eye drops have preservatives added to 
prevent bacterial contamination and allow for long-term 
use of multidose bottles. Benzalkonium chloride (BAK), a 
quaternary ammonium detergent, is the most commonly used 
preservative in ophthalmic drops.65 BAK is known to have 
cytotoxic side effects on the cornea and conjunctiva, leading 
to metaplasia and tear film breakdown.66–69 The Preservative 
exposure and surgical outcome study (PESO) demonstrated 
that increased preoperative exposure to BAK is a risk factor 
for glaucoma surgery failure, probably due to the baseline 
inflammation level and the trend toward higher inflammation 
response in these eyes.70 
Travoprost 0.004% was reformulated in 2010 to replace 
BAK with polyquaternium-1 (polyquad), a preservative 
derived from BAK but thought to be gentler on the ocular 
surface. Despite some studies demonstrating less cell dam-
age and inflammatory infiltration with polyquad-preserved 
travoprost,71,72 recent findings revealed that polyquad itself 
might have detrimental effects on cell membrane integrity 
and induce cytotoxicity.73,74
A completely preservative-free (PF) travoprost formula-
tion has been marketed in the US since 2006. This formulation 
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uses a proprietary preservative system called sofZia (Alcon 
Laboratories, Inc, Fort Worth, TX, USA), an ionic buffer 
containing borate, sorbitol, propylene, glycol, and zinc. 
sofZia chemical components are not significantly toxic to 
the ocular surface, but are able to maintain an antimicrobial 
environment. The sofZia system meets the US Pharmacopeia 
standards for antimicrobial activity. The efficacy and safety 
of PF travoprost were demonstrated in a multicenter, random-
ized, parallel-group study among 690 patients diagnosed with 
POAG and OHT.75 Patients were randomized to treatment 
with BAK-preserved or PF travoprost 0.004% for 3 months. 
IOP was assessed at 8 am, 10 am, and 4 pm at week 2, week 6, 
and month 3. Assuming a similar diurnal baseline IOP for 
the two groups (25.7 mmHg and 25.9 mmHg, respectively, 
for the PF and the BAK-preserved group), mean IOP reduc-
tions across all nine study visits and times ranged from 7.3 
to 8.5 mmHg for PF travoprost and from 7.4 to 8.4 mmHg 
for travoprost preserved with BAK. No significant difference 
was found between the two formulations.
Patients on treatment with BAK-preserved PGs and with 
tolerability issues might have some benefits in replacing 
their therapy with PF travoprost. In a study by Henry et al 
691 patients under therapy with latanoprost or bimatoprost 
with added BAK were shifted, due to intolerance issues, to 
a therapy with PF travoprost.76 Patients were surveyed using 
the Ocular Surface Disease Index to evaluate ocular surface 
disease symptoms prior to and 3 months after changing their 
therapy. PF travoprost demonstrated improved mean Ocular 
Surface Disease Index scores compared to either latanoprost 
or bimatoprost (P0.001) and in 70.2% of the patients symp-
toms were reduced in severity by at least one level.
A recent new formulation of travoprost 0.003%, preserved 
with polyquad, was accepted by the FDA in May 2014. While 
BAK and other preservatives may have an effect on the ocular 
surface and influence the risk of glaucoma surgery failure, 
chronic exposition to active agents certainly has the potential 
for inducing at least some cellular toxicity and ocular surface 
changes.70,77 This should be taken into account especially 
for PGs, which are known to be proinflammatory agents. 
Approval of travoprost 0.003% by the FDA was granted by a 
clinical trial of 3 months duration comparing the IOP lower-
ing efficacy of travoprost 0.003% to travoprost 0.004% in 
patients affected by POAG and OHT.78 A total of 864 patients 
were enrolled, with 840 (97%) completing the study. IOP 
parameters were compared between treatments at week 2, 
week 6, and month 3 for each time-point (8 am, 10 am, and 
4 pm). Mean differences in IOP between travoprost 0.003% 
and travoprost 0.004% at the nine assessments ranged 
from -0.3 to 0.0 mmHg, indicating statistical equivalence 
between treatments. Other studies on travoprost 0.003% for-
mulation are expected to clarify its role in clinical practice.
Travoprost in pediatric populations
In December 2014, travoprost 0.004% was approved by the 
European Medicines Agency (EMA) for use in pediatric 
patients, aged 2 months to 18 years, affected by OHT or glau-
coma. The European approval was based on a 12-week, Phase III, 
multicenter, double-masked, randomized, parallel-group 
study recruiting 152 patients.79 Patients were randomized to 
treatment with travoprost 0.004% once-a-day in the evening 
or treatment with timolol (0.5% or 0.25%) twice daily for 
12 weeks. In the travoprost group, the effect on IOP was 
seen after the 2nd week of treatment and was consistently 
maintained throughout the 12-week study period. No 
difference was found in IOP reduction between travoprost 
and timolol. The most frequent adverse events in this pedi-
atric population were conjunctival hyperemia and eyelash 
growth, similarly to adult patients.
To the best of our knowledge, only one other study, a 
retrospective study by Yanovitch et al, evaluated efficacy and 
safety of travoprost 0.004% in a cohort of 57 pediatric patients 
(75 eyes), affected by congenital and juvenile glaucoma.80 
In this study, travoprost was not used as first-line therapy, and 
was generally added to other glaucoma medications. From 
the original cohort, only 26 eyes were included in the efficacy 
analysis, with a mean baseline IOP of 26.3±6.6 mmHg. After 
1 month of travoprost treatment, mean IOP was reduced to 
21.0±7.0 mmHg (P0.001). Fourteen eyes (54%) showed 
a decrease in IOP of 15% from baseline after 1 month of 
treatment. Seventy-five eyes were included in the safety 
analysis. Travoprost was generally well tolerated and only 
five eyes discontinued the medication due to ocular adverse 
events: four because of conjunctival hyperemia and one 
because of ocular irritation. Eyelash growth was observed 
in all patients. Even if no definite conclusion can be drawn 
from this study, due to the retrospective design and the small 
sample size, travoprost seemed more effective in patients 
affected by juvenile and aphakic glaucoma, while only one-
third of congenital glaucoma patients (4/11) showed an IOP 
reduction 15%.
Safety of travoprost
Ocular hyperemia is a common side effect of PGs, mainly 
mediated by scleral and conjunctival vasodilation.81 
The mechanism behind vasodilation is complex and probably 
involves release of nitric oxide stimulated by PGs82 and response 
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from sensory nerves.83 Other mediators may be involved, such 
as calcitonin gene-related peptide and substance P.84
Netland et al found clinically significant changes in ocu-
lar hyperemia in 49.5% of patients treated with travoprost 
0.004%, in 27.6% of patients treated with latanoprost, and 
in 14.0% of patients treated with timolol.52 However, mean 
hyperemia score in all the treatments groups was less than 1 
on a scale of 0–3, indicating that, on average, the majority of 
patients experienced none/trace to mild hyperemia. Hyper-
emia was evident since the first follow-up visit, at week 2. 
Konstas et al found no difference in ocular hyperemia 
incidence among patients treated with travoprost 0.004% 
dosed in the evening or in the morning.45 Respectively, 
hyperemia was encountered in 27% and in 33% of patients 
(P=0.6). In another study, the same authors noted that con-
junctival hyperemia was seen twice as often with travoprost 
(15 patients) as with latanoprost (six patients).59
Darker and longer eyelashes are a well-described side 
effect of PG treatment. Although PG receptors involved in 
the development and regrowth of the hair follicle have been 
identified in the outer root sheath of dermal papilla,85,86 it is 
not known whether PGs exert their effects on them. Misdi-
rected growth, resulting in lash ptosis or trichiasis requiring 
intervention, has been reported.87 A meta-analysis by Li et al 
found major risks of eyelash changes in patients treated 
with travoprost compared to latanoprost (odds ratio: 3.8, 
P0.001).54 However, only two studies were included in the 
analysis, so results must be interpreted with caution. Eyelash 
changes are probably a reversible side effect and cessation of 
the treatment may restore the original condition.88,89
Iris darkening is a common side effect of all PGs, but 
not all eyes are equally at risk. Homogenous green or blue 
irises are less prone to develop iris darkening than irises with 
brown patches on blue, green, or gray.90 Duration of treatment 
seems to be a risk factor, and generally iris darkening appears 
during the first 6–8 months; over 90% of patients that are 
going to develop iris darkening will have already done so 
after 2 years of treatment.91 In a 12-month study, Netland et al 
found iris pigmentation change in 3.1% of patients under 
therapy with travoprost 0.004% and in 5.2% of patients 
under therapy with latanoprost.52 In a shorter 6-month study 
comparing travoprost to bimatoprost, Cantor et al found no 
iris pigmentation change in the cohort of patients random-
ized to treatment with travoprost 0.004% (n=81), while one 
patient developed iris darkening in the bimatoprost group 
(n=76).60 As iris pigmentation is probably a function of 
treatment duration, one might expect greater incidence of 
this side effect in the long-term. Riva et al evaluated safety 
of travoprost treatment in a 5-year follow-up study, and found 
a cumulative incidence of iris darkening of 27.7%,49 which 
is comparable with the 33.4% rate reported in a 5-year study 
on latanoprost.91 
It is not completely understood why PGs induce iris dark-
ening and why this side effect is more common in patients 
with mixed-color irises than others. Increase in iris pigmenta-
tion is probably due to an increase in melanin content within 
cytoplasm of melanocytes,81,92 while an increase in melano-
cyte proliferation is unlikely. It has been demonstrated that 
PGF2α can stimulate, directly or indirectly, melanogenesis, 
probably though FP receptor action.93–95 Although iris pig-
mentation is thought to be only a cosmetic effect, it should 
be discussed with patients at the beginning of the therapy, 
especially in patients with mixed-color irises. Moreover, this 
side effect should always be evaluated when the patient needs 
a unilateral therapy, trying to avoid macroscopic differences 
between eyes (Figure 4).
Few case reports in literature pointed out a potential risk 
of cystoid macular edema in patients under therapy with 
Figure 4 Heterochromia due to unilateral therapy with travoprost in right eye.
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travoprost and other PGs.96–98 Proinflammatory properties 
of PGs may induce a breakdown in the blood–retinal bar-
rier, causing loss of fluids in the macular region. This could 
be particularly true when a direct communication between 
the anterior and posterior chamber is present, such as after 
surgical capsular rupture or in aphakia. However, literature 
data are lacking. Generally, it seems that the risk of cystoid 
macular edema is extremely low to nonexistent in low-risk 
eyes (no intraocular surgeries or uveitis) and that even in 
high-risk eye the incidence is relatively low.81 While therapy 
with PGs may not be the first-line therapy in aphakic patients 
or in patients with posterior capsule rupture, no absolute 
contraindication is actually established.
Anterior uveitis has been linked to travoprost therapy 
in few case reports.99–103 Cessation of travoprost therapy 
and topical steroids administration are usually sufficient to 
improve clinical conditions and resolve uveitis. In some cases 
a rechallenge with travoprost may cause a new onset, demon-
strating the causality between therapy and uveitis.103 Integrity 
of the blood–aqueous barrier was studied by Cellini et al in 
a cohort of 60 glaucoma patients randomized to treatment 
with travoprost, latanoprost, and bimatoprost.104 Anterior 
chamber flare and cells were evaluated at baseline and after 
3 and 6 months of therapy. The authors found a significant 
increase in cells and flare at the 3- and 6-month visit for all 
PGs, whereas a slight reduction in cells and flare was noted 
between 3 and 6 months. Only at the 3-month visit did travo-
prost induce a higher rate of flare and cells than bimatoprost. 
Even though a link between travoprost therapy and anterior 
uveitis may be assumed, it should be kept in mind that uveitis 
is an extremely rare side effect of this therapy.
Conclusion
PGs are highly effective in reducing IOP in patients affected 
by POAG and OHT. Studies show that travoprost reduces 
IOP on average by 27%–30%, with no tachyphylaxis in the 
long-term.43,44,49 Efficacy of travoprost has been demonstrated 
in the daytime but also in a 24-hour period, with persistency 
of its pharmacological effect until 84 hours from the last 
administration.47,48 Convenience of one-day dosing and 
minor side effects make this drug a good choice as first-line 
therapy in glaucoma patients. Moreover, the combination of 
travoprost with timolol in an FC can limit side effects due to 
concomitant administration of the two drugs, and is advisable 
for patients requiring a greater IOP reduction or at greater 
risk of glaucoma progression. Future researches are needed 
to evaluate the role of the new formulation of travoprost 
0.003% in current clinical practice. 
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